DK2144919T3 - Flertrins-syntese af ibandronat - Google Patents
Flertrins-syntese af ibandronat Download PDFInfo
- Publication number
- DK2144919T3 DK2144919T3 DK08718377.8T DK08718377T DK2144919T3 DK 2144919 T3 DK2144919 T3 DK 2144919T3 DK 08718377 T DK08718377 T DK 08718377T DK 2144919 T3 DK2144919 T3 DK 2144919T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- pentyl
- process according
- formula
- pentylamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
Claims (11)
1. Fremgangsmåde til fremstillingen af 3-(N-methyl-N-pentyl) amino-1-hydroxypropan-l,l-diphosphonsyre, mononatriumsalt, monohydrat med formlen I
I hvilken fremgangsmåde omfatter: hydrolysen af N-methyl-N-pentyl-p-alaninmethylesteren for at få N-methyl-N-pentyl^-alaninet med formlen IV
IV tilsætning af diethylcarbonat azeotrop destillation for at fjerne resterende vand og efterfølgende biphosphorylering af forbindelsen med formel IV ved hjælp af phosphorylchlorid og phosphorsyre og dannelsen af mononatriumsaltet, monohydrat.
2. Fremgangsmåde til fremstillingen af 3-(N-methyl-N-pentyl) amino-1-hydroxypropan-l,l-diphosphonsyre, mononatriumsalt, monohydrat med formlen I
I hvilken fremgangsmåde omfatter: (a) kondensation af N-pentylamin med benzaldehyd for at få N-benzyliden-N-pentylaminen med formel II
II (b) transformation af N-benzyliden-N-pentylaminen til N-methyl-N-pentylaminen med et methyleringsmiddel (c) omdannelse af N-methyl-N-pentylaminen med methylacrylat til N-methyl-N-pentyl^-alanin-methylesteren med formlen III
III (d) hydrolyse af N-methyl-N-pentyl^-alaninmethylester for at få N-methyl-N-pentyl-3-alaninen med formlen IV
IV tilsætning af diethylcarbonat azeotrop destillation for at fjerne resterende vand (e) bisphosphorylering af forbindelsen med formel IV ved hjælp af phosphorylchlorid og phosphorsyre og dannelsen af mononatriumsaltet, monohydrat.
3. Fremgangsmåde ifølge krav 2, kendetegnet ved at kondensationen i trin a) udføres i et egnet opløsningsmiddel ved en temperatur på 40 til 90°C.
4. Fremgangsmåde ifølge krav 2 eller 3, kendetegnet ved at transformationen i trin b) udføres ved en temperatur på 80 til 110°C.
5. Fremgangsmåde ifølge kravene 2 til 4, kendetegnet ved at transformationen i trin b) udføres med dimethylsulfat som methyleringsmiddel.
6. Fremgangsmåde ifølge kravene 2 til 5, kendetegnet ved at omdannelsen i trin c) udføres i et egnet opløsningsmiddel ved en reaktionstemperatur på 10 til 65°C.
7. Fremgangsmåde ifølge kravene 1 til 6, kendetegnet ved at hydrolysen udføres i vand ved en temperatur på 90 til 100°C.
8. Fremgangsmåde ifølge kravene 1 til 6, kendetegnet ved at hydrolysen udføres i fortyndede mineralsyrer.
9. Fremgangsmåde ifølge kravene 1 til 8, kendetegnet ved at for bisphosphoryleringen i trin e) er molærforholdet N-methyl-N-pentyl-p-alanin/ phosphorylchlorid/phosphorsyre valgt fra 1,0 : 3,0 : 3,0 til 1,0 : 1,4 : 2,4.
10. Fremgangsmåde ifølge kravene 1 til 9, kendetegnet ved at for bisphosphoryleringen i trin e) er reaktionstemperaturen valgt fra 60 til 100°C.
11. Fremgangsmåde ifølge kravene 1 til 10, kendetegnet ved at dannelsen af mononatriumsaltet, fremkaldes monohydrat ved at justere den vandige reaktionsblandings pH fra 3,5 til 6,0, med en vandig opløsning af natriumhydroxid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07105915 | 2007-04-11 | ||
| PCT/EP2008/053876 WO2008125483A2 (en) | 2007-04-11 | 2008-04-01 | Multi step synthesis of ibandronate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2144919T3 true DK2144919T3 (da) | 2015-12-14 |
Family
ID=39722497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08718377.8T DK2144919T3 (da) | 2007-04-11 | 2008-04-01 | Flertrins-syntese af ibandronat |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7662990B2 (da) |
| EP (1) | EP2144919B1 (da) |
| JP (1) | JP5220843B2 (da) |
| KR (1) | KR101150662B1 (da) |
| CN (1) | CN101679465B (da) |
| AU (1) | AU2008238058B2 (da) |
| BR (1) | BRPI0809548A8 (da) |
| CA (1) | CA2683971C (da) |
| DK (1) | DK2144919T3 (da) |
| ES (1) | ES2558383T3 (da) |
| HU (1) | HUE026660T2 (da) |
| IL (1) | IL201307A (da) |
| MX (1) | MX2009010850A (da) |
| PL (1) | PL2144919T3 (da) |
| SI (1) | SI2144919T1 (da) |
| WO (1) | WO2008125483A2 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010524967A (ja) * | 2007-04-19 | 2010-07-22 | ドクター・レディーズ・ラボラトリーズ・リミテッド | イバンドロン酸ナトリウム多形体 |
| WO2011016738A1 (en) * | 2009-08-05 | 2011-02-10 | Zaklady Farmaceutyczne Polpharma Sa | A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate |
| CN101863919B (zh) * | 2010-07-05 | 2011-11-23 | 武汉同源药业有限公司 | 一种化合物伊班膦酸钠的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3919321A (en) | 1966-11-08 | 1975-11-11 | Hoffmann La Roche | Halo-substituted-5H-dibenzo{8 a,d{9 cyclohepten-5-ones |
| DE2534391C2 (de) * | 1975-08-01 | 1983-01-13 | Henkel KGaA, 4000 Düsseldorf | 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren |
| US4220611A (en) | 1978-06-29 | 1980-09-02 | Sandoz, Inc. | Polyoxyalkylene bridged phosphate esters |
| DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3808074A1 (de) | 1988-03-11 | 1989-09-21 | Henkel Kgaa | Verfahren zur herstellung von azacycloalkan-2,2-diphosphonsaeuren |
| DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US6562974B2 (en) | 2000-02-01 | 2003-05-13 | The Procter & Gamble Company | Process for making geminal bisphosphonates |
| WO2003097655A1 (en) * | 2002-05-17 | 2003-11-27 | Teva Pharmaceutical Industries Ltd. | Use of certain diluents for making bisphosphonic acids |
| ATE451380T1 (de) * | 2003-08-21 | 2009-12-15 | Sun Pharmaceuticals Ind Ltd | Verfahren zur herstellung von bisphosphonsäureverbindungen |
| DE602004032577D1 (de) * | 2003-12-23 | 2011-06-16 | Alchymars S P A | Amorphe Form das Natriumsalzes der Ibandronsäure |
| MX2007000087A (es) | 2004-06-23 | 2007-11-06 | Teva Pharma | Acido ibandronico solido y cristalino. |
| EP1713489B1 (en) | 2004-08-23 | 2011-01-19 | Teva Pharmaceutical Industries Ltd | Crystalline form of ibandronate sodium and processes for preparation thereof |
| US7214818B2 (en) | 2004-10-29 | 2007-05-08 | Hoffmann-La Roche Inc. | Method for synthesizing bisphosphonate |
| EP1848728B1 (en) * | 2005-02-01 | 2014-06-11 | F.Hoffmann-La Roche Ag | Ibandronate polymorph a |
| EP1848727B1 (en) | 2005-02-01 | 2015-06-17 | F.Hoffmann-La Roche Ag | Ibandronate polymorph b |
| WO2007013097A1 (en) * | 2005-07-25 | 2007-02-01 | Natco Pharma Limited | Improved process for the preparation of ibandronate sodium |
-
2008
- 2008-04-01 US US12/060,314 patent/US7662990B2/en active Active
- 2008-04-01 EP EP08718377.8A patent/EP2144919B1/en not_active Not-in-force
- 2008-04-01 CA CA2683971A patent/CA2683971C/en not_active Expired - Fee Related
- 2008-04-01 WO PCT/EP2008/053876 patent/WO2008125483A2/en active Search and Examination
- 2008-04-01 ES ES08718377.8T patent/ES2558383T3/es active Active
- 2008-04-01 AU AU2008238058A patent/AU2008238058B2/en not_active Ceased
- 2008-04-01 MX MX2009010850A patent/MX2009010850A/es active IP Right Grant
- 2008-04-01 SI SI200831566T patent/SI2144919T1/sl unknown
- 2008-04-01 DK DK08718377.8T patent/DK2144919T3/da active
- 2008-04-01 KR KR1020097023419A patent/KR101150662B1/ko not_active IP Right Cessation
- 2008-04-01 BR BRPI0809548A patent/BRPI0809548A8/pt not_active IP Right Cessation
- 2008-04-01 JP JP2010502488A patent/JP5220843B2/ja active Active
- 2008-04-01 PL PL08718377T patent/PL2144919T3/pl unknown
- 2008-04-01 CN CN200880011546XA patent/CN101679465B/zh not_active Expired - Fee Related
- 2008-04-01 HU HUE08718377A patent/HUE026660T2/en unknown
-
2009
- 2009-10-01 IL IL201307A patent/IL201307A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20080255386A1 (en) | 2008-10-16 |
| CA2683971C (en) | 2013-02-26 |
| SI2144919T1 (sl) | 2016-02-29 |
| CN101679465A (zh) | 2010-03-24 |
| WO2008125483A2 (en) | 2008-10-23 |
| HUE026660T2 (en) | 2016-07-28 |
| EP2144919A2 (en) | 2010-01-20 |
| JP2010523614A (ja) | 2010-07-15 |
| BRPI0809548A2 (pt) | 2014-09-16 |
| BRPI0809548A8 (pt) | 2018-10-16 |
| WO2008125483A3 (en) | 2008-12-18 |
| KR101150662B1 (ko) | 2012-05-29 |
| US7662990B2 (en) | 2010-02-16 |
| IL201307A (en) | 2013-10-31 |
| IL201307A0 (en) | 2010-05-31 |
| CA2683971A1 (en) | 2008-10-23 |
| JP5220843B2 (ja) | 2013-06-26 |
| EP2144919B1 (en) | 2015-12-02 |
| AU2008238058A1 (en) | 2008-10-23 |
| CN101679465B (zh) | 2013-08-21 |
| PL2144919T3 (pl) | 2016-05-31 |
| AU2008238058B2 (en) | 2010-12-02 |
| KR20090130117A (ko) | 2009-12-17 |
| ES2558383T3 (es) | 2016-02-03 |
| MX2009010850A (es) | 2009-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1807090B9 (en) | Process for the preparation of ibandronate | |
| JP2008517964A5 (da) | ||
| JP5015006B2 (ja) | 〔１−ヒドロキシ−２−（３−ピリジニル）エチリデン〕ビスホスホン酸及びその２．５水和物モノナトリウム塩の製造方法 | |
| DK2144919T3 (da) | Flertrins-syntese af ibandronat | |
| US20080300408A1 (en) | Process for Preparing a Pure Polymorphic Form of 3-Pyridyl-1-Hydroxyethylidine-1, 1-Bisphosphonic Acid Sodium Salt | |
| EP1981896B1 (en) | An improved process for the preparation of risedronate sodium hemi-pentahydrate | |
| EP1803727B1 (en) | Improved process for manufacture of 4-amino-hydroxybutylidene-1,1-bisphosphonic acid and its salts | |
| NO331532B1 (no) | Fremgangsmate for fremstilling av salter av metylenbisfosfonsyre | |
| JP2008538556A (ja) | ヒドロキシル化イソフラボンの製造方法 |